Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia

Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal

Resveratrol supplementation may improve cardiovascular risk factors and cognitive parameters in patients with schizophrenia taking antipsychotics?

Randomized, double-blind, placebo-controlled trial comparing supplementation with resveratrol or placebo in patients diagnosed with schizophrenia.

Inclusion Criteria:

Men 18-65 years old, diagnosed with schizophrenia according to DSM-IV and ICD-10, which are in clozapine medication for at least 6 months.

Exclusion Criteria:

Patients will be excluded from the study:

• Have a diagnosis of diabetes
• Use other antipsychotic drugs, clozapine beyond
• Using medicines for diabetes or dyslipidaemia
• Accept not participate in any stage of the research.